In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiesi's First Step Into Germany

Executive Summary

Buying a foothold in Germany filled an important gap in Chiesi's European expansion strategy. But the privately owned Italian group may have to loosen up its dealmaking style to continue to clinch the deals it needs.

You may also be interested in...



Dompé Looks Beyond In-Licensing

Mid-sized Italian drug firm Dompé has made its name as an astute local marketer. Yet the company is now talking up its in-house R&D programs, acknowledging that a pure in-licensing model may not work forever.

Menarini: East of Eden

When Alberto Aleotti began running Menarini in the mid-1960s, drug companies in Italy did not do research, because the country offered no patent protection. He believed patents would be key to the industry's growth, and campaigned for years on the issue. As soon as Italy began issuing patents in 1978, Menarini began doing research. Aleotti expected the work would take time to bear fruit, and so he concentrated on helping foreign partners sell their innovative products in Italy and beyond. Menarini's highly successful co-marketing of Glaxo's Zantac spurred other large firms to seek its help too. They signed deals with no upfront fees, only royalties, and Menarini's revenues and infrastructure grew steadily through the 80s. The company's research efforts advanced in parallel with revenue growth, which slowed with scandal-induced price cuts in the 90s. As yet, the work has yielded little of commercial value-but Aleotti says he expected it would take this long. Marketing remains Menarini's core strength, but changing industry dynamics are making novel products harder to come by. The company considers several of its drug candidates very promising, and is now striving to move them along faster. Industry observers are watching the progress of this exceedingly private firm, which says it will soon announce agreements of great strategic importance.

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel